← Eichor
Study identifier: NCT06001047 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Head Acupuncture Treat Residual Symptoms After Canalith Repositioning Procedure for BPPV

Condition: Benign Paroxysmal Positional Vertigo  ·  Sponsor: Xi'an No.3 Hospital

PhaseNA
Planned participants120
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersNo

About this study

Benign paroxysmal positional vertigo (BPPV) is the most common peripheral vestibular disorder, and currently, manual repositioning techniques are often used for treatment. However, up to 30%-50% of patients may experience residual symptoms such as non-rotational dizziness, heaviness, instability, and emotional disturbances even after successful repositioning, which significantly impacts their daily functioning and quality of life. Electroacupuncture therapy has been proven to be an effective treatment for dizziness and has been applied to various vestibular disorder patients. However, the efficacy of electroacupuncture on the residual effects of successfully repositioned BPPV patients remains unclear. This study aims to explore the effectiveness of three regimens: electroacupuncture, betahistine in patients with residual symptoms after successful manual repositioning.

This description comes directly from the study's public registry record.

Talk to the study team

Mingze Chang, PhD  ·  029+8661816100  ·  changmingze191@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Xi'an No3 HospitalXi'an, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06001047